Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JFL Life SciencesNSE:JFLLIFE -4.55%67 Return-on-Tangible-Equity is 11.09% as of Mar. 2025, which is 14% above its 10-year median of 9.73. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 67/100 and a GF Value™ of ₹35.94 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 901 Drug Manufacturers companies, JFL Life Sciences ranks better than 59.71% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JFL Life Sciences's annualized net income for the quarter that ended in Mar. 2025 was ₹41.6 Mil. JFL Life Sciences's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ₹375.2 Mil. Therefore, JFL Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 11.09%.
The historical rank and industry rank for JFL Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:JFLLIFE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.03 Med: 9.73 Max: 30.94
Current: 11.09
During the past 7 years, JFL Life Sciences's highest Return-on-Tangible-Equity was 30.94%. The lowest was 6.03%. And the median was 9.73%.
NSE:JFLLIFE's Return-on-Tangible-Equity is ranked better than 59.71% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:JFLLIFE: 11.09
JFL Life Sciences (NSE:JFLLIFE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JFL Life Sciences Return-on-Tangible-Equity Related Terms
JFL Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:JFLLIFE vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.09% mean?
JFL Life Sciences (NSE:JFLLIFE) has a Return-on-Tangible-Equity of 11.09% as of Mar. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JFL Life Sciences and its competitors. This is 14% above median its historical median of 9.73. Over the past decade, JFL Life Sciences' Return-on-Tangible-Equity has ranged from 6.03 to 30.94. According to the industry distribution chart, JFL Life Sciences ranks #363 out of 901 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is JFL Life Sciences' Return-on-Tangible-Equity too high?
JFL Life Sciences' current Return-on-Tangible-Equity of 11.09% is 14% above median its 10-year median of 9.73. Over the past 10 years, this metric has ranged from a low of 6.03 to a high of 30.94. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. JFL Life Sciences' value of 11.09% is 40.4% above this industry median. Based on the distribution chart, JFL Life Sciences ranks #363 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #363 out of 901 companies for Return-on-Tangible-Equity. This puts JFL Life Sciences in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. JFL Life Sciences' value of 11.09% is 40.4% above this benchmark. Historically, JFL Life Sciences' own Return-on-Tangible-Equity has ranged from 6.03 to 30.94 over the past decade. While the company's 10-year median is 9.73 vs. the industry median of 7.90, JFL Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current Return-on-Tangible-Equity of 11.09% is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current Return-on-Tangible-Equity is 11.09%, which is 14% above median its own 10-year median of 9.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.94, compared to a current price of ₹10.50 — trading 70.8% below its estimated fair value. The current Return-on-Tangible-Equity is 11.09%, which is 14% above median its 10-year median of 9.73 and 40.4% above the Drug Manufacturers industry median of 7.90. JFL Life Sciences' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Return-on-Tangible-Equity is 11.09% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.50 is trading 70.8% below its estimated GF Value™ of ₹35.94.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
Return-on-Tangible-Equity: 11.09% (14% above median its 10-year median of 9.73)
GF Value™: ₹35.94 vs. price of ₹10.50 (70.8% below fair value)
Industry Position: 40.4% above the Drug Manufacturers median (#363 of 901)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
67GF Score
Get the complete analysis for NSE:JFLLIFE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 
